Clinical trials: Target Lesion
- Condition Target Lesion
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Alzheimer Disease, Alzheimer Disease (AD)
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Trial name
- DU-PRISM (NCT07142278)
- Testing
- DUVAX 200 µg, DUVAX 400 µg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Healthy
PET Study of Repeated ASN51 in Healthy Volunteers
This is a phase 1, open-label, dose escalation, positron emission tomography (PET) study to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamics (PD) response in peripheral blood mononuclear cells (PBMCs)…
- Trial name
- NCT05725005
- Testing
- ASN51
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
Colorectal Cancer
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"
The primary objective of this study is to assess the sensitivity for colorectal cancer (CRC) and specificity of the mt-sDNA 2.0 test.
- Trial name
- NCT04144738
- Testing
- mt-sDNA 2.0 screening test, FIT test, Colonoscopy
- Where
- 195 sites in United States
- Volunteers
- 26,758 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
NAFLD, NASH - Nonalcoholic Steatohepatitis
Development and Validation of a Multi-target, Blood-based NAFLD Diagnosis Test
Multi-omics approach was used to identify patterns of serological biomarkers to diagnose NAFLD. The purpose of this study is to develop and validate a blood-based assay to diagnose NAFLD by collecting blood sample from healthy…
- Trial name
- NCT05108415
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- HBI Solutions Inc.
Colorectal Cancer
An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now
The primary objective is to confirm the specificity of a multi-target stool DNA test (mt-sDNA), Cologuard, in an average risk population, ages 45-49.
- Trial name
- NCT03728348
- Testing
- mt-sDNA screening test, Colonoscopy
- Where
- 39 sites in United States
- Volunteers
- 983 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Healthy Volunteers, Cardiometabolic Diseases
A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People
The study is testing a new study medicine, which is being tested as a potential medicine to treat cardiometabolic diseases. The aim of this study is to see if the study medicine is safe, how it works in participants body, and…
- Trial name
- NCT06336005
- Testing
- NNC6022-0001
- Where
- Netherlands
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers, Ulcerative Colitis
Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis
The primary purpose of this study is to determine if single and multiple doses of BMS-986184 are safe and well tolerated in healthy male and female subjects.
- Trial name
- NCT02864264
- Testing
- BMS-986184
- Where
- 3 sites in Australia, Georgia and 1 more
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing
- Trial name
- NCT04787302
- Testing
- CVL-231
- Where
- 2 sites in United States, Belgium
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC
Healthy
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects
This is the first clinical study with the BMS-986147 compound in healthy subjects. The purpose of this study is to guide the dose range and dose frequency for future studies with BMS-986147 and will provide guidelines for…
- Trial name
- NCT02293629
- Testing
- BMS-986147
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Colon Cancer
Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality
The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
- Trial name
- NCT04124406
- Testing
- Cologuard
- Where
- United States
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Healthy
SurePulse Oximeter - a Targeted Oxygenation Observation
This clinical investigation will investigate how accurate the SurePulse VS and SurePulse VS Patch (VSP) are for measuring blood oxygen levels (oxygen saturation).
- Trial name
- SPO-TOO (NCT05756816)
- Testing
- SurePulse VSP, SurePulse VS
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Surepulse Medical Limited
Pain, Inflammatory
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)
This study is the first administration of GSK3858279 in humans and will be conducted in two parts: Part A will consist of a single ascending dose escalation design to evaluate safety, tolerability, PK, TE and immunogenicity of…
- Trial name
- NCT03485365
- Testing
- GSK3858279 IV, GSK3858279 SC
- Where
- 5 sites in Germany, Poland and 1 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Musculoskeletal Pain
Effectiveness of Four Orthotic Insoles on Pain in the Lower Body Associated With Musculoskeletal Stress
This was an open-label, single-centre, parallel-group clinical investigation, to evaluate the effectiveness and in-use tolerability of a range of four orthotic insoles on target areas of pain in the lower body, associated with…
- Trial name
- NCT04746755
- Testing
- Orthotic Insole: Lower Back, Orthotic Insole: Heel, Orthotic Insole: Knee to Heel
- Where
- United Kingdom
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Healthy
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080
Anticalins® are engineered human proteins that are able to bind specific target molecules. The Anticalin PRS-080#022-DP to be investigated in this study is directed against hepcidin and is intended for treatment of anemia of…
- Trial name
- NCT02340572
- Testing
- PRS-080#022-DP
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pieris Pharmaceuticals GmbH
Opiate Withdrawal Syndrome
A Study of Oral Ibogaine in Opioid Withdrawal
Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of an initial single ascending dose escalation stage to determine the maximum tolerated dose (MTD) or treat-to-target dose (TTD) in healthy volunteers, followed by a…
- Trial name
- NCT05029401
- Testing
- DMX-1002
- Where
- 2 sites in United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- atai Therapeutics, Inc.
Target Drug-related Adverse Events
Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens
The purpose of this study is to determine whether the addition of selective pharmacogenomic (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced by a reduction in Target Drug-related…
- Trial name
- SPHERE (NCT02625155)
- Testing
- Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
- Where
- United States
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- InSource Diagnostics
Colo-rectal Cancer
Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.
The primary objective of this sub-study, 2018-10B, is to collect blood specimens to assess new biomarkers for the detection of Colorectal Cancer (CRC).
- Trial name
- NCT03741166
- Testing
- Blood Sample Collection
- Where
- 37 sites in United States
- Volunteers
- 871 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Colorectal Cancer
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"
The primary objective of this sub-study, 2019-01B, is to collect blood specimens for research use in the development and validation of a blood-based test for colorectal cancer (CRC).
- Trial name
- NCT04144751
- Testing
- Blood Sample Collection
- Where
- 194 sites in United States
- Volunteers
- 23,494 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Healthy Participants
Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51
This is a phase 1, open-label, positron emission tomography (PET) study in healthy adult participants to determine the relationship between plasma concentration and brain target occupancy of ASN51 following a single oral dose.
- Trial name
- NCT06390098
- Testing
- ASN51
- Where
- United Kingdom
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
Neuropathic Pain
Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults
The goal of this clinical trial is to learn if ASCT-83 is safe and well-tolerated and measure how ASCT-83 is absorbed, distributed, and eliminated from the body over time. The study will be conducted in healthy adults.
- Trial name
- NCT07363395
- Testing
- ASCT-83
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Alcamena Stem Cell Therapeutics